Bridging the Gap in Elimination of Hepatitis C Virus among People Who Use Drugs in South Korea.
作者信息
Kim Beom Kyung
机构信息
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
出版信息
Gut Liver. 2025 Sep 15;19(5):635-636. doi: 10.5009/gnl250396.
Abstract
摘要
相似文献
1
Bridging the Gap in Elimination of Hepatitis C Virus among People Who Use Drugs in South Korea.弥合韩国吸毒人群丙型肝炎病毒消除差距
Gut Liver. 2025 Sep 15;19(5):635-636. doi: 10.5009/gnl250396.
2
Prevalence, Clinical Characteristics, and Treatment Status of Hepatitis C Virus Infection among People Who Use Drugs in South Korea: A Prospective Multicenter Study.韩国吸毒人群丙型肝炎病毒感染的患病率、临床特征及治疗状况：一项前瞻性多中心研究
Gut Liver. 2025 Sep 15;19(5):725-734. doi: 10.5009/gnl240451. Epub 2025 May 30.
3
Progress Toward Hepatitis C Virus Elimination among People Living with HIV-Hepatitis C Virus Coinfection in Canada.加拿大艾滋病毒-丙型肝炎病毒合并感染患者中丙型肝炎病毒消除进展情况。
Can Liver J. 2025 Feb 25;8(1):49-62. doi: 10.3138/canlivj-2024-0042. eCollection 2025 Feb.
4
Modeling the impact of changing drug markets and structural determinants on HCV and/or HIV transmission among people who inject drugs in the United States: A rural and urban comparison.模拟美国毒品市场变化和结构决定因素对注射吸毒者中丙型肝炎病毒（HCV）和/或人类免疫缺陷病毒（HIV）传播的影响：城乡比较
Int J Drug Policy. 2025 Sep;143:104925. doi: 10.1016/j.drugpo.2025.104925. Epub 2025 Jul 23.
5
Global, regional, and national estimates of hepatitis C virus (HCV) infection incidence among people who inject drugs and number of new annual HCV infections attributable to injecting drug use: a multi-stage analysis.注射吸毒者中丙型肝炎病毒（HCV）感染发病率以及每年因注射吸毒导致的新增HCV感染病例数的全球、区域和国家估计：一项多阶段分析
Lancet Gastroenterol Hepatol. 2025 Apr;10(4):315-331. doi: 10.1016/S2468-1253(24)00442-4. Epub 2025 Feb 21.
6
Associations of hepatitis C virus (HCV) antibody positivity with opioid, stimulant, and polysubstance injection among people who inject drugs (PWID) in rural U.S. communities.美国农村社区注射吸毒者中丙型肝炎病毒（HCV）抗体阳性与阿片类药物、兴奋剂和多物质注射之间的关联。
Int J Drug Policy. 2023 Oct 6:104222. doi: 10.1016/j.drugpo.2023.104222.
7
A systematic review of Hepatitis C virus treatment uptake among people who inject drugs in the European Region.对欧洲区域注射毒品者丙型肝炎病毒治疗接受情况的系统评价。
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S16. doi: 10.1186/1471-2334-14-S6-S16. Epub 2014 Sep 19.
8
Reinfection following successful direct-acting antiviral therapy for hepatitis C virus infection among people with recent injecting drug use: the SHARP-C study.近期有注射吸毒史的丙型肝炎病毒感染者接受直接抗病毒治疗成功后的再次感染：SHARP-C研究
Int J Drug Policy. 2025 Sep;143:104859. doi: 10.1016/j.drugpo.2025.104859. Epub 2025 Jun 18.
9
Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life.最小化监测的丙型肝炎病毒治疗方法对健康相关生活质量的影响。
Qual Life Res. 2025 Jun;34(6):1683-1694. doi: 10.1007/s11136-025-03922-1. Epub 2025 Feb 28.
10
Understanding hepatitis C virus reinfections in England in the context of eliminating viral hepatitis as a public health concern.在将病毒性肝炎作为公共卫生问题加以消除的背景下，了解英格兰的丙型肝炎病毒再感染情况。
Int J Drug Policy. 2025 Sep 11;145:105005. doi: 10.1016/j.drugpo.2025.105005.
本文引用的文献
1
Patient preferences for simplified hepatitis C testing modalities among people at risk of hepatitis C infection in Australia: the SELECT study.澳大利亚丙型肝炎感染风险人群对简化丙型肝炎检测方式的患者偏好：SELECT研究
Int J Drug Policy. 2025 Sep;143:104871. doi: 10.1016/j.drugpo.2025.104871. Epub 2025 Aug 5.
2
Prevalence, Clinical Characteristics, and Treatment Status of Hepatitis C Virus Infection among People Who Use Drugs in South Korea: A Prospective Multicenter Study.韩国吸毒人群丙型肝炎病毒感染的患病率、临床特征及治疗状况：一项前瞻性多中心研究
Gut Liver. 2025 Sep 15;19(5):725-734. doi: 10.5009/gnl240451. Epub 2025 May 30.
3
Liver disease trends in the Asia-Pacific region for the next 50 years.未来50年亚太地区的肝病趋势。
Clin Mol Hepatol. 2025 Jul;31(3):671-684. doi: 10.3350/cmh.2025.0043. Epub 2025 Mar 4.
4
Self-testing strategy to eliminate hepatitis C as per World Health Organization's goal: Analysis of disease burden and cost-effectiveness.根据世界卫生组织目标消除丙型肝炎的自我检测策略：疾病负担与成本效益分析
Clin Mol Hepatol. 2025 Jan;31(1):166-178. doi: 10.3350/cmh.2024.0484. Epub 2024 Oct 4.
5
Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan.动态变化的代谢相关脂肪性肝病患者的慢性丙型肝炎病毒根除后：一个全国性的登记研究在台湾。
Clin Mol Hepatol. 2024 Oct;30(4):883-894. doi: 10.3350/cmh.2024.0414. Epub 2024 Jul 29.
6
Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.《2023年丙型肝炎指南更新：美国肝病研究学会-美国感染病学会关于丙型肝炎病毒感染检测、管理及治疗的建议》
Clin Infect Dis. 2023 May 25. doi: 10.1093/cid/ciad319.
7
Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review.注射吸毒的流行病学、与注射相关的危害的流行率，以及注射吸毒者的行为和环境风险的暴露情况：系统评价。
Lancet Glob Health. 2023 May;11(5):e659-e672. doi: 10.1016/S2214-109X(23)00057-8. Epub 2023 Mar 27.
8
Next-generation sequencing analysis of hepatitis C virus resistance-associated substitutions in direct-acting antiviral failure in South Korea.韩国直接作用抗病毒药物失败中丙型肝炎病毒耐药相关替换的下一代测序分析。
Clin Mol Hepatol. 2023 Apr;29(2):496-509. doi: 10.3350/cmh.2022.0345. Epub 2023 Mar 6.
9
The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015.2009 年至 2015 年韩国全国丙型肝炎病毒血清流行率变化及与护理的关联状况。
Hepatol Int. 2019 Sep;13(5):599-608. doi: 10.1007/s12072-019-09975-y. Epub 2019 Aug 20.
Zotero 插件